STATEMENT OF NEED
Thyroid cancer is one of the most prevalent cancers in the United States. An estimated 56,870 new cases are diagnosed annually, and 2,010 people die of the disease (ACS, 2017). Thyroid cancer is typically more aggressive in men than women and becomes increasingly lethal in those older than age 40 (NCCN, 2016). There are three primary subtypes: differentiated (including papillary, follicular, and Hürthle), medullary, and anaplastic. The differentiated subtype is the most common, accounting for approximately 94% of cases (ACS, 2016). Although surgical resection may be curative and 10-year survival rates are high, the dearth of data from well-designed trials has led to confusion over optimal management strategies for individual patients (NCCN, 2016). The medullary subtype accounts for 4% of cases, with nearly half presenting with unresectable or metastatic disease. No curative systemic therapies are available for these patients, and the 5-year overall survival rate is only 28% (ACS, 2016). The anaplastic subtype has the worst prognosis, with no effective therapies available. The 1-year survival rate is a dismal 20%, and the disease-specific mortality rate is nearly 100% (NCCN, 2016).
Oncologists, endocrinologists, surgeons, and other health care professionals involved in the treatment of patients with thyroid cancer.
Upon completion of this activity, participants should be able to:
- Assess risk-adapted approaches to the management of thyroid cancer
- Evaluate efficacy and safety data on novel therapies for differentiated and medullary thyroid cancer
- Apply posttreatment monitoring strategies to ensure optimal outcomes for patients with thyroid cancer
Jochen H. Lorch, MD, MS (Chairperson)
Assistant Professor of Medicine
Harvard Medical School
There is no fee to participate in or claim CME credit for this activity.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and i3 Health. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates: 1 ILNA point may be applied toward:
Professional Practice; Survivorship; Treatment .................1 point
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced. Relevant financial relationships exist between the following individuals and commercial interests:
Penn State College of Medicine staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Jochen H. Lorch, MD, MS discloses that he has served as a consultant/advisor for Eisai and has received research grants from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, and Millennium.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
- Watch the online video
- Pass the posttest with a score of ≥80%
- Complete the activity evaluation
- Download or print their Certificate of Credit
UNAPPROVED USE DISCLOSURE
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.The information presented in this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Penn State College of Medicine, i3 Health, or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
This activity is supported by an independent educational grant from Sanofi Genzyme.